Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.

Acta biomaterialia - 15 Sept 2023

Huang Ri, Du Hong, Cheng Liang, Zhang Peizhuo, Meng Fenghua, Zhong Zhiyuan

Abstract excerpt

Pancreatic cancer (PC) stands as a most deadly malignancy due to few effective treatments in the clinics. KRAS G12D mutation is a major driver for most PC cases, and silencing of KRAS G12D is considered as a potential therapeutic strategy for PC, which is nevertheless crippled by lacking a pragmatic delivery system for siRNA against KRAS G12D (siKRAS). Here, we report that cRGD peptide-modified bioresponsive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Mice
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pancreatic Neoplasms

Share to Peptides

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA, Small Interfering

Source

Identifiers

PMID: 37451658
DOI: 10.1016/j.actbio.2023.07.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.PMID 37451658Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

Mutant KRAS is a druggable target for pancreatic cancer.Semantic proximity Read ↗

Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.Semantic proximity Read ↗

Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.Semantic proximity Read ↗

Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer CellsSemantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer.Semantic proximity Read ↗

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.Semantic proximity Read ↗

Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer.Semantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Semantic proximity Read ↗

Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptidesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.